NASDAQ:NKTR 延时15分钟

成交量

Robert B. Chess: Robert B. Chess was the founder of Penederm, Inc., founded in 1986, where the title held was President from 1986 to 1989. Mr. Chess was the founder of Biota Technology, Inc., founded in 2013, where the title held was Chairman. Current jobs include Chairman at Nektar Therapeutics since 2007, Chairman at Issio Solutions, Inc., Chairman at BigHat Biosciences, Inc. since 2022, Lead Independent Director at Twist Bioscience Corp. since 2018, Director at NanOasis, Inc. since 2012, Director at Pelvalon, Inc., Trustee at California Institute of Technology since 2006, and Trustee at Committee for Economic Development. Former jobs include Chairman & Chief Executive Officer at OPX Biotechnologies, Inc. from 2007 to 2015, Chairman at Germitec SA, Chairman at Bio Ventures for Global Health, Director at Pharsight Corp. from 2000 to 2006, Director at CymaBay Therapeutics, Inc. in 2009, Director at CoTherix, Inc. from 2004 to 2007, Director at Biotechnology Innovation Organization from 2009 to 2009, Associate Director-Economic & Domestic Policy at The White House from 1990 to 1991, Principal at Intel Corp., and Principal at Metaphor Computer Systems, Inc. Education includes an MBA degree from Harvard University conferred in 1980 and undergraduate education at California Institute of Technology.

Roy A. Whitfield: Roy A. Whitfield was the founder of Incyte Corp., established in 1991, where the title held was Director from 2003 to 2014. The current job is Lead Independent Director at Nektar Therapeutics, starting in 2019 and ongoing since joining the company in 2000. Former jobs include Executive Chairman at BioSeek, Inc.; Independent Director at Illumina, Inc. from 2011 to 2017; Director at Station X, Inc.; Director at Solexa, Inc. from 2006 to 2007; Director at Sciona, Inc.; Principal at The Boston Consulting Group, Inc.; Principal at Technicon Instruments Corp. from 1984 to 1989; Principal at Cooper Biomedical, Inc.; and Advisor at InterWest Venture Management Co. Education includes an MBA from Stanford University and an undergraduate degree from the University of Oxford.

Howard W. Robin: Howard W. Robin is President, Chief Executive Officer & Director at Nektar Therapeutics since 2007. Formerly, Mr. Robin was President, Chief Executive Officer & Director at Sirna Therapeutics, Inc. from 2001 to 2006. From 1984 to 2001, held roles at Berlex, Inc., including Director-Business Planning & Development from 1987 to 2001 and Vice President & General Manager from 1991 to 2001. Also served as Director at Acologix, Inc., Biotechnology Innovation Organization, and The Bay Area Bioscience Association. Worked as Senior Associate at Arthur Andersen LLP. Served as Trustee at Fairleigh Dickinson University. Education includes an undergraduate degree from Fairleigh Dickinson University, conferred in 1974.; 旧服务已下线，请迁移至 http://api.fanyi.baidu.com

R. Scott Greer: R. Scott Greer was the founder of Abgenix, Inc., founded in 1996, where the title held was Chairman from 2002 to 2007. Mr. Greer is the founder of Numenor Ventures LLC, founded in 2002, holding the title of Managing Director since 2002. The current job is Independent Director at Nektar Therapeutics, starting in 2010. Former jobs include Chairman at Ablexis LLC from 2010 to 2016; Chairman at Sirna Therapeutics, Inc. from 2005 to 2009; Chairman at Acologix, Inc.; Chairman at Calimmune, Inc. from 2015 to 2017; Independent Director at StemCells, Inc. from 2011 to 2016; Director at CV Therapeutics, Inc. from 2001 to 2004; Director at Illumina, Inc. from 2001 to 2005; Independent Director at Inogen, Inc. from 2015 to 2021; Director at BAROnova, Inc. from 2009 to 2013; Director at AnaptysBio, Inc. from 2007 to 2008; Director at Affymax, Inc. from 2000 to 2004; Independent Director at Project Sage Oldco, Inc. from 2014 to 2018; Director at Auspex Pharmaceuticals, Inc. from 2014 to 2015; Director at Versartis, Inc. from 2014 to 2018; Director at Auspex, Inc.; Director at Aravive, Inc. from 2014 to 2017; Senior Vice President-Corporate Development at Cell Genesys, Inc. in 1996; Senior Vice President-Corporate Development at Genetics Institute LLC from 1985 to 1991. Education includes an undergraduate degree from Whitman College in 1981 and an MBAistration from Harvard Business School in 1985.

Jeffrey Robert Ajer: Jeffrey Robert Ajer is currently an Independent Director at Nektar Therapeutics since 2017 and a Director at Viridian Therapeutics, Inc. starting in 2025. Former roles include Director-Purchasing Worldwide at Bausch Health Americas, Inc. from 1986 to 1999; Senior Director-Sales Operations, Bids & Contracts at SangStat Medical Corp.; Independent Director at True North Therapeutics, Inc.; Chief Commercial Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. from 2012 to 2014; Vice President-Global Transplant Operations at Genzyme Corp. from 2003 to 2005; and Chief Commercial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. from 2013 to 2024. Education includes undergraduate and MBA degrees from the University of California, Irvine.

Diana M. Brainard: Dr. Diana M. Brainard, MD, is an Independent Director at Affinia Therapeutics, Inc., an Independent Director at Nektar Therapeutics and an Entrepreneur Partner at MPM BioImpact LLC. She is on the Board of Directors at Affinia Therapeutics, Inc. and Nektar Therapeutics. Dr. Brainard was previously employed as a Chief Executive Officer & Director by AlloVir, Inc. and a Senior VP-HIV & Emerging Viral Infections by Gilead Sciences, Inc. She received her undergraduate degree from Brown University and a doctorate degree from Tulane University School of Medicine.

Nektar Therapeutics